Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Israel
  4. TEL AVIV STOCK EXCHANGE
  5. XTL Biopharmaceuticals Ltd.
  6. News
  7. Summary
    XTLB   IL0010854979

XTL BIOPHARMACEUTICALS LTD.

(XTLB)
End-of-day quote TEL AVIV STOCK EXCHANGE  -  2023-01-25
0.0420 ILS   -4.55%
01/21Xtl Biopharmaceuticals : Immediate Report of Meeting
PU
01/20Xtl Biopharmaceuticals : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FEBRUARY 23, 2023 - Form 6-K
PU
2022Xtl Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K
PU
SummaryQuotesChartsNewsCalendarCompanyFinancialsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

XTL Biopharmaceuticals : CONDENSED INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K

08/24/2022 | 10:58am EST

CONDENSED INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

AS OF JUNE 30, 2022

INDEX

Page
Condensed Interim Unaudited Consolidated Financial Statements - in U.S. dollars:
Unaudited Condensed Consolidated Statements of Financial Position 2
Unaudited Condensed Consolidated Statements of Comprehensive Income (Loss) 3
Unaudited Condensed Statements of Changes in Equity 4
Unaudited Condensed Consolidated Statements of Cash Flows 5-6
Notes to Unaudited Condensed Consolidated Financial Statements 7-10

- - - - - - - - - - - -

XTL BIOPHARMACEUTICALS LTD.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

June 30, December 31,
2022 2021
U.S. dollars in thousands
ASSETS
CURRENT ASSETS:
Cash and cash equivalents 2,346 2,969
Marketable securities 2,810 3,158
Prepaid expenses and other current assets 220 110
5,376 6,237
NON-CURRENT ASSETS:
Fixed assets, net 1 1
Intangible assets, net 380 380
381 381
Total assets 5,757 6,618
LIABILITIES AND EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses 172 231
NON-CURRENT LIABILITIES:
Warrant liability 22 1,054
Total liabilities 194 1,285
EQUITY ATTRIBUTABLE TO EQUITY HOLDERS OF THE COMPANY:
Share capital - ordinary shares of NIS 0.1 par value: authorized shares - 1,450,000,000 on June 30, 2022 and December 31, 2021; issued and outstanding: 544,906,149 on June 30, 2022 and December 31, 2021; 14,120 14,120
Additional paid in capital 146,326 146,326
Reserve from transactions with non-controlling interests 20 20
Accumulated deficit (154,903 ) (155,133 )
Total equity 5,563 5,333
Total liabilities and equity 5,757 6,618

The accompanying notes are an integral part of the interim consolidated financial statements

Approval date of the interim consolidated financial statements by the Company's Board: August 23, 2022.

2

XTL BIOPHARMACEUTICALS LTD.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

Six months ended

June 30,

Three months ended

June 30,

2022 2021 2022 2021
U.S. dollars in thousands (except per share data)
Research and development expenses (21 ) (18 ) (15 ) (6 )
General and administrative expenses (430 ) (517 ) (187 ) (297 )
Operating loss (451 ) (535 ) (202 ) (303 )
Revaluation of marketable securities (348 ) 968 (572 ) (68 )
Revaluation of warrant liability 1,032 (1,289 ) 495 (776 )
Other finance income 8 5 5 3
Other finance expenses (20 ) (14 ) (11 ) (6 )
Finance income (expenses), net 672 (330 ) (83 ) (847 )
Total profit (loss) for the period 221 (865 ) (285 ) (1,150 )
Basic and diluted earnings (loss) per share
0.000 (0.002 ) (0.001 ) (0.002 )
Weighted average number of Ordinary Shares used in computing basic and diluted earnings (loss) per share
544,906,149 522,758,917 544,906,149 527,794,273

The accompanying notes are an integral part of the interim consolidated financial statements

3

XTL BIOPHARMACEUTICALS LTD.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

Six months ended June 30, 2022

Share

capital

Additional
paid in
capital
Accumulated
deficit
Reserve
from
transactions
with non-
controlling
interests

Total

equity

U.S. dollars in thousands
Balance as of January 1, 2022 14,120 146,326 (155,133 ) 20 5,333
Profit for the period
-
-
221
-
221
Share-based payment to employees and non-employees -
-
9
-
9
Balance as of June 30, 2022 (unaudited) 14,120 146,326 (154,903 ) 20 5,563
Six months ended June 30, 2021

Share

capital

Additional
paid in
capital
Accumulated
deficit
Reserve
from
transactions
with non-
controlling
interests

Total

equity

U.S. dollars in thousands
Balance as of January 1, 2021 13,182 146,015 (155,605 ) 20 3,612
Loss for the period -
-
(865 )
-
(865 )
Exercise of warrants to ordinary shares 421 91
-
-
512
Share-based payment to employees and non-employees -
-
23
-
23
Balance as of June 30, 2021 (unaudited) 13,603 146,106 (156,447 ) 20 3,282

The accompanying notes are an integral part of the interim consolidated financial statements

4

XTL BIOPHARMACEUTICALS LTD.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six months ended

June 30,

2022 2021
U.S. dollars in thousands
Cash flows from operating activities:
Net income (loss) for the period 221 (865 )
Adjustments to reconcile loss to net cash used in operating activities (a) (841 ) 148
Net cash used in operating activities (620 ) (717 )
Cash flows from investing activities:
Interest income from bank deposit 8 5
Net cash from investing activities 8 5
Cash flows from financing activities:
Net cash provided by financing activities
-
-
Decrease in cash and cash equivalents (612 ) (712 )
Loss from exchange rate differences on cash and cash equivalents (11 ) (1 )
Cash and cash equivalents at the beginning of the period 2,969 3,631
Cash and cash equivalents at the end of the period 2,346 2,918

The accompanying notes are an integral part of the interim consolidated financial statements

5

XTL BIOPHARMACEUTICALS LTD.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Six months ended

June 30,

2022 2021

U.S. dollars in thousands

(a) Adjustments to reconcile loss to net cash used in operating activities:
Income and expenses not involving operating cash flows:
Depreciation (* ) (* )
Revaluation of marketable securities 348 (968 )
Revaluation of warrant liability (1,032 ) 1,289
Share-based payment transactions to employees and non-employees 9 23
Loss from exchange rate differences on cash and cash equivalents 11 1
Interest income (8 ) (5 )
Other financial income - (1 )
(672 ) 339
Changes in operating asset and liability items:
Increase in prepaid expenses and other current assets (110 ) (195 )
Increase (decrease) in other accounts payable (59 ) 4
(169 ) (191 )
(841 ) 148
(b) Non-cash activities:
Exercise of warrants - 512
(*) less than 1 thousands.

The accompanying notes are an integral part of the interim consolidated financial statements

6

XTL BIOPHARMACEUTICALS LTD.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1: GENERAL

A general description of the Company and its activity:

XTL Biopharmaceuticals Ltd. (the "Company") is engaged in the development of therapeutics for the treatment of unmet medical needs of Systemic Lupus Erythematosus ("SLE"). In 2014, the Company signed a licensing agreement with Yeda, as amended on September 6, 2015, to develop hCDR1, a Phase II-ready asset for the treatment of SLE. The Company was incorporated under the Israeli Companies Law on March 9, 1993. The registered office of the Company is located at 5 Badner Street, Ramat Gan, Israel.

The Company's American Depository Shares ("ADSs") are listed for trading on the Nasdaq Capital Market ("Nasdaq") and its ordinary shares are traded on the Tel-Aviv Stock Exchange ("TASE").

The Company has a wholly-owned subsidiary, Xtepo Ltd. ("Xtepo"), which was incorporated in Israel. The Company and Xtepo are heretofore referred to as the Group.

NOTE 2: BASIS OF PREPARATION OF THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS
a. The condensed consolidated financial information of the Company as of June 30, 2022 and for the respective interim periods of six and three months then ended ("interim financial information") has been prepared in accordance with IAS 34, "Interim Financial Reporting" ("IAS 34"). This interim financial information does not contain all the information and disclosures that are required in the framework of the annual financial statements. This interim financial information should be read in conjunction with the annual financial statements for 2021 and the accompanying notes which have been prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board.
b. Estimates - the preparation of the interim consolidated financial statements requires the Company's management to make judgments and to use accounting estimates and assumptions that have an effect on the application of the Company's accounting policies and on the reported amounts of assets, liabilities and expenses. Actual results could differ from those estimates.
In the preparation of these interim consolidated financial statements, the significant judgment exercised by management in applying the Company's accounting policies and the uncertainties involved in the key sources of the estimates were identical to those in the annual consolidated financial statements for the year ended December 31, 2021.

7

XTL BIOPHARMACEUTICALS LTD.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 3: SIGNIFICANT ACCOUNTING POLICIES

The Company's significant accounting policies and methods of computation adopted in the preparation of the interim consolidated financial statements are consistent with those followed in the preparation of the annual consolidated financial statements for 2021.

NOTE 4: MARKETABLE SECURITIES
a. All marketable securities held by the Company constitute Level 1 financial instruments, as defined in IFRS 13 - "Fair Value Measurement". Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.
b. The Company holds the following financial instruments:
June 30, December 31,
2022 2021
U.S. dollars in thousands
Marketable securities 2,810 3,158

The entire investment in marketable securities is classified as a financial asset at fair value through profit or loss. As of June 30, 2022 the Company holds approximately 1% of InterCure Ltd's shares (the shares are traded at the Tel-Aviv Stock Exchange - "TASE").

c. Changes in marketable securities for the six months ended June 30, 2022 and same period in 2021 were all from changes in the fair value (no sales occurred). During the six and three months ended June 30, 2022, the Company recorded finance expense at the amount of $348 thousands and $572 thousands, respectively, with respect of marketable securities revaluation.
NOTE 5: WARRANT LIABILITY

During the year ended December 31, 2017, the Company raised gross funds amounted to $5,300 thousand by issuance of 2,400,000 ADS's and 2,450,000 warrants to purchase the same amount of ADS's. The warrants shall be exercisable six months following the issuance date and will expire five and one-half years from the issuance date. The number of warrants and their exercise price could be adjusted upon standard anti-dilution protection clauses and subject to a cashless exercise mechanism.

The Company accounted for the warrants issued to investors with a cashless exercise mechanism as a non-current liability according to provisions of IAS 32. The Company measured the warrants at fair value by using a Black and Scholes model. The warrants were measured in each reporting period. Changes in the fair value were recognized in the Company's statement of comprehensive income (loss) as financial income or expense, as appropriate. The warrants were classified as level 3.

8

XTL BIOPHARMACEUTICALS LTD.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5: WARRANT LIABILITY (Cont.)

The Company used the following assumptions to estimate the Investors' warrants:

June 30,
2022
December 31,
2021
Risk-free interest rate (1) 1.48-1.68 % 0.19 %
Expected volatility (2) 67.52 % 60.83-62.46 %
Contractual term life (in years) (3) 0.13-0.18 0.63-0.68
Dividend yield (4) 0 % 0 %
(1) Risk-free interest rate - based on yield rates of non-index linked U.S. Federal Reserve treasury bonds.
(2) Expected volatility - was calculated based on actual historical share price movements of the Company over a term that is equivalent to the contractual term of the option.
(3) Expected life - the expected life was based on the expiration date of the warrants.
(4) Dividend yield - was based on the fact that the Company has not paid dividends to its shareholders in the past and does not expect to pay dividends to its shareholders in the future.
Outstanding warrants:

The table below summarizes the outstanding warrants as of June 30, 2022:

Warrants
outstanding to
purchase ADSs
Number of
shares
exercisable
Issuance
date
Exercise price
in USD
(per warrant)
Expiration
date
600,000 60,000,000 February 23, 2017 4.1 August 23, 2022
1,197,500 119,750,000 March 21, 2017 2.3 September 21, 2022
1,797,500 179,750,000

On February 16, 2022, 5,000,000 warrants from the February 17, 2017 round expired.

During the six and three months ended June 30, 2022, the Company recorded finance income at the amount of $1,032 thousands and $495 thousands, respectively, with respect of Warrant liability revaluation.

9

XTL BIOPHARMACEUTICALS LTD.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 5: WARRANT LIABILITY (Cont.)

A summary of changes in warrants issued by the Company during the six months period ended June 30, 2022 and 2021 is as follows:

Fair value measurements using input type
Level 1 Level 2 Level 3 Total
U.S. dollars in thousands
Balance as of January 1, 2021
-
-
2,637 2,637
Loss recognized in profit or loss in finance income (expense), net
-
-
1,289 1,289
Disposal
-
-
(512 ) (512 )
Warrant liability as of June 30, 2021
-
-
3,414 3,414
Warrant liability as of December 31, 2021
-
-
1,054 1,054
Gain recognized in profit or loss in finance income (expense), net
-
-
(1,032 ) (1,032 )
Warrant liability as of June 30, 2022
-
-
22 22
NOTE 6: SUBSEQUENT EVENT

On August 23, 2022, 60,000,000 warrants from the February 23, 2017 round expired.

10

Disclaimer

XTL Biopharmaceuticals Ltd. published this content on 24 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 August 2022 14:57:04 UTC.


ę Publicnow 2022
All news about XTL BIOPHARMACEUTICALS LTD.
01/21Xtl Biopharmaceuticals : Immediate Report of Meeting
PU
01/20Xtl Biopharmaceuticals : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON FE..
PU
2022Xtl Biopharmaceuticals : Report Of Foreign Private Issuer - Form 6-K
PU
2022XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Nine Months Ended Septembe..
CI
2022Xtl Biopharmaceuticals : CONDENSED INTERIM UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS - F..
PU
2022XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Second Quarter and Six Mon..
CI
2022Xtl Biopharmaceuticals : Report of Periodic or Interim Report
PU
2022XTL Biopharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 3..
CI
2021Xtl Biopharmaceuticals : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON JA..
PU
2021Xtl Biopharmaceuticals Ltd. Reports Earnings Results for the Second Quarter Ended June ..
CI
More news
Financials (USD)
Sales 2021 - - -
Net income 2021 0,44 M - -
Net cash 2021 6,13 M - -
P/E ratio 2021 122x
Yield 2021 -
Capitalization 6,71 M 6,66 M -
EV / Sales 2020 -
EV / Sales 2021 -
Nbr of Employees 5
Free-Float 88,8%
Chart XTL BIOPHARMACEUTICALS LTD.
Duration : Period :
XTL Biopharmaceuticals Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Shlomo Spokone Shalev Chief Executive Officer & Executive Director
Itay Weinstein Chief Financial Officer
Doron Turgeman Chairman & Chief Executive Officer
Daphna Paran Medical Director
Dobroslav Melamed Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
XTL BIOPHARMACEUTICALS LTD.2.44%7
MODERNA, INC.7.58%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.55%28 465
SEAGEN INC.9.46%26 117